GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » GF Value

Transition Therapeutics (Transition Therapeutics) GF Value : $0.00 (As of May. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-06), Transition Therapeutics's share price is $1.5248. Transition Therapeutics's GF Value is $0.00. Therefore, Transition Therapeutics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Transition Therapeutics is Not Valued.

Transition Therapeutics  (NAS:TTHI) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Transition Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=1.5248/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transition Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » GF Value
Comparable Companies
AGE ASX:MDC TSX:BU BKK:IP OPNT OHEL:HRTIS XPAR:GNRO NLNK MRNS GNCA XKRX:038070 ROCO:6696 TSXV:MPH OSTO:DMYD B CYCN XTER:CNWK TSE:4570 KZR BVXV XMAD:BIO
Traded in Other Exchanges
N/A
Address
Website
http://www.transitiontherapeutics.com
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045